Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Trial register facet

Phase 2 trial records — page 3

92 records at phase 2.

Showing 0 records on this page

Records

92 documents · page 3 of 4

Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.

RecordCompoundPhaseStatusDesignRandomisedYearCertainty
LIVERAGE-BIOMARKERprogramme recordLiraglutidePhase 2ReportedRandomised, double-blind, placebo-controlled2016Very low
LIVERAGE-ADHERENCEprogramme recordLiraglutidePhase 2ReportedObservational2016Very low
TB4-PH2-EPIDERMOLYSIS-BODY-COMPprogramme recordThymosin beta-4Phase 2ReportedRandomised, double-blind, placebo-controlled2016Very low
LIVERAGE-OLEprogramme recordLiraglutidePhase 2ReportedSingle-arm open-label2016Very low
TB4-PH2-EPIDERMOLYSIS-QOLprogramme recordThymosin beta-4Phase 2ReportedRandomised, double-blind, placebo-controlled2016Very low
LIVERAGE-ELDERLYprogramme recordLiraglutidePhase 2ReportedRandomised, double-blind, placebo-controlled2016Very low
AOD-OA-PH2AOD-9604Phase 2ReportedRandomised, double-blind, placebo-controlled2015Low
TB4-PH2-DRYEYEThymosin beta-4Phase 2ReportedRandomised, double-blind, placebo-controlled722015Low
TB4-PH2-DRYEYE-ELDERLYprogramme recordThymosin beta-4Phase 2ReportedRandomised, double-blind, placebo-controlled2015Very low
TB4-PH2-DRYEYE-OLEprogramme recordThymosin beta-4Phase 2ReportedSingle-arm open-label2015Very low
TB4-PH2-DRYEYE-ADHERENCEprogramme recordThymosin beta-4Phase 2ReportedObservational2015Very low
TB4-PH2-DRYEYE-BIOMARKERprogramme recordThymosin beta-4Phase 2ReportedRandomised, double-blind, placebo-controlled2015Very low
AOD-OA-PH2-BODY-COMPprogramme recordAOD-9604Phase 2ReportedRandomised, double-blind, placebo-controlled2015Very low
KISS-IVF-TRIGGERKisspeptin-10Phase 2ReportedSingle-arm open-label602014Low
TB4-PH2-VENOUSULCERThymosin beta-4Phase 2ReportedRandomised, double-blind, placebo-controlled722013Low
TB4-PH2-VENOUSULCER-OLEprogramme recordThymosin beta-4Phase 2ReportedSingle-arm open-label2013Very low
TB4-PH2-VENOUSULCER-ELDERLYprogramme recordThymosin beta-4Phase 2ReportedRandomised, double-blind, placebo-controlled2013Very low
TB4-PH2-VENOUSULCER-BIOMARKERprogramme recordThymosin beta-4Phase 2ReportedRandomised, double-blind, placebo-controlled2013Very low
TB4-PH2-VENOUSULCER-ADHERENCEprogramme recordThymosin beta-4Phase 2ReportedObservational2013Very low
IPA-PH2-POIIpamorelinPhase 2TerminatedRandomised, double-blind, placebo-controlled2011Not rated
IPA-PH2-POI-ADHERENCEprogramme recordIpamorelinPhase 2ReportedObservational2011Very low
IPA-PH2-POI-BIOMARKERprogramme recordIpamorelinPhase 2ReportedRandomised, double-blind, placebo-controlled2011Very low
IPA-PH2-POI-ELDERLYprogramme recordIpamorelinPhase 2ReportedRandomised, double-blind, placebo-controlled2011Very low
IPA-PH2-POI-OLEprogramme recordIpamorelinPhase 2ReportedSingle-arm open-label2011Very low

page 3 of 4

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.